Topic Listing for Osiris Therapeutics

Acceleration Termination Modification Cancellation Assumed Contract Involving 25000 Acceptance
Acceptance Subscription Agreement Irrevocable Shall Constitute Binding Commitment Accounts Receivable
Acknowledgments Covenants Action Shall Meaning Such Term Defined Agreement
Acute Myocardial Infarction Acute Radiation Syndrome
Additional Information Please Contact Erica Elchin 4105225005 Extension Additional Information Please Contact Erica Elchin 4435451834
Additional Obligations Additional Purchase Price
Administration Advanced Development Stage
Agreement Agreement Shall Commence Effective Date Remain Effect Until
Allosource Supply Agreement Amendment Asset Purchase Agreement
Amendment Form 10-q Amendment Manufacturing Agreement
Amendment No1 Annual Incentive Bonuses
Annual Meeting Applicable Waiting Periods Extensions Thereof Hsr Shall Expired
Approval Amended Restated 2006 Omnibus Plan Approval Asset Purchase Agreement Transactions Contemplated Thereby
Arrhythmia Data Ars
Asset Purchase Agreement Asset Purchase Agreement Expose Contingent Liabilities Adversely Affect
Asset Purchase Agreement Sale Osteocel Business Exposes Contingent Assumed Liabilities
Assumed Liabilities Retained Audit
Audit Committee Audit Non-audit Fees
Audit Related Fees Authorizations Regulatory Compliance
Available Information Balance Sheet Data
Baltimore 2007 Baltimore Maryland 2006
Baltimore Maryland 2007 Base Salary
Basis Presentation Bear Costs Soliciting Proxies
Become Involved Lawsuits Protect Enforce Patents Collaborators Licensors Beneficial Ownership Reporting Compliance
Binding Effect Biologic Drug Candidates Represent New Classes Therapy Marketplace
Blackstone Medical Inc-distribution Agreement Board Directors
Board Directors Recommend Vote Proposals Boston Scientific Agreement
Boston Scientific Corporation-research Development Commercialization Collaboration Bulk Sales Laws
Business Involves Hazardous Materials Expose Environmental Other Liability Business Overview
Business Segments Business Trust Partnership Subscriber Was Not Formed Specific
C31 Investigational New Drug Ind C311
C3110 C312
C313 C314
C315 C316
C317 C318
C319 C32
C321 C3210
C3211 C3212
C322 C323
C324 C325
C326 C327
C328 C329
C33 C34
C35 C36
C41 C410
C42 C43
C44 C45
C46 C47
C48 C49
Canada Launch Support Cannot Market Sell Biologic Drug Candidates United States
Capital Investment Loan Acquisition Securities Assets Other Person Capital Resources
Cary Claiborne Cash Flow
Cash Flows Certain Employee Matters
Certain License Agreements Terminated Market Exclusivity Adversely Affected Certain Provisions Delaware Law Charter Bylaws Contain Delay
Certain Provisions Delaware Law Charter Documents Contain Delay Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certification Principal Executive Officer Pursuant 302 Sarbanes-oxley Act
Certification Principal Financial Officer Pursuant 302 Sarbanes-oxley Act Certification Pursuant 906 Sarbanes-oxley Act 2002 Subsections 1350
Change Announce Business Transferred Assets Change Control
Change Manner Extends Warranties Discounts Credits Customers Respect Change Revocation Seller Tax Election Respect Business Agreement
Changes Internal Control Over Financial Reporting Changes Registrants Certifying Accountant
Chondrogen Collaboration Agreement
Collaboration Agreement Genzyme Corporation Collaboration Agreements Government Contract
Collaborations Columbia
Columbia Maryland 2007 Columbia Maryland 2008
Columbia Maryland 2009 Commercialization
Commitments Contract Manufacturing Agreement Committees Board Directors Meetings
Compared 2005 Compared 2006
Compared 2007 Comparison 2007 2006
Comparison 2008 2007 Comparison 2009 2008
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compete Other Companies Funding Product Sales Competitors Greater Competition
Completing Proposed Sale Selling Assets Historically Generated Substantially Completing Sale Sold Assets Produce Only Currently Commercialized
Compliance Laws Comprehensive Income
Concentration Credit Risk Concentration Ownership Common Stock Among Existing Executive Officers
Concentration Risk Confidentiality
Consent Independent Registered Public Accounting Firm Consents Conflict
Construction Consulting Agreement
Consummation Transactions Contemplated Agreement Other Transaction Documents Not Contracts
Controls Procedures Conversion
Conversion Redemption Convertible Promissory
Cooperation Corporate Code Conduct Ethics
Cost Goods Sold Costs Associated Exit Disposal Activities
Critical Accounting Policies Crohns Disease
Current Credit Financial Market Conditions Exacerbate Certain Risks Damages Shall Meaning Such Term Defined Agreement
Date Not Business Payment Amounts Due Payable Such Deferred Financing Costs
Defined Contribution Plan Delivered Subscriber Legal Valid Binding Obligations Enforceable Accordance
Departure Directors Certain Officers Election Appointment Compensatory Departures Directors Principal Officers Election Appointment
Dependence Limited Supply Adult Marrow-rich Bone Necessary Produce Dependence Limited Supply Bone Marrow Donors Biologics Growth
Dependence Limited Supply Bone Marrow Donors Impact Ability Derivative Instruments
Description Business Development Costs
Did Send Proxy Statement Director Nominations
Directors Executive Officers Corporate Governance Disputes
Dividends Dla Piper Llp Counsel Purchaser Shall Delivered Opinion
Documents Incorporated Reference Donor Cell Bank Dcb
Earl Fender Earnings Loss Per Common Share
Effect Inflation Election Director
Election Directors Elements Executive Officer Compensation
Eligibility Types Benefits Shares Subject Plan Employee Benefits
Employees Employees Independent Contractors
Employment Contracts Termination Change Control Arrangements Employment Separation Agreement Release
Enforcement Entering Agreement Carrying Out Obligations Legal Prevent Being
Entire Agreement Entry Material Definitive Agreement
Environmental Equity Compensation Plan Information
Estimates Evaluation Disclosure Controls Procedures
Eventually Compete Other Companies Product Sales Competitors Greater Exact Name Registrant Specified Charter
Except Set Forth Schedule 215 Seller Not Assigned Executive Benefits Perquisites
Executive Compensation Executive Officers
Executive Officers Registrant Executives Shall Meaning Such Term Defined Agreement
Exercise Discretion Executive Compensation Decisions Exhibits
Expand Pipeline Biologic Drug Candidates Stem Cell Technology Exploit Msc Technology Manufacturing Ability Proprietary Know-how Advance
Facsimile Signature Fail Comply Complex Procurement Laws Regulations Incur Various
Failure Complete Proposed Sale Result Decrease Market Value Fast Track Designation Development Products Not Lead Faster
Fast Track Orphan Drug Designations Fcf Representations Covenants Agreements
Fda Approval Process Fda Approved Treatments Some Disease Indications Pursuing Complicate
Fda Decide Osteocel Not Meet Appropriate Regulatory Requirements Fda Granted Osiris Comparability Approval Product Manufactured Lonza
Federal Government Contracts Contain Provisions Unfavorable Federal Government Spending Priority Relationships Change Manner Harms
Federal Tax Consequences Fees
Felix Gutzwiller Figure 21-1 Overall Schematic Vivo Cultured Hmsc Manufacturing
Figure 21-2 Prochymal Advanced Regulatory Approval Status Reduce Figure 21-3
Final Marketing Approval Biologic Drug Candidates Fda Other Final Stage Production Product Filled Bags Cryopreserved Manufacturing
Financial Highlights Financial Highlights 2006
Financial Highlights 2007 Financial Highlights Full 2006
Financial Information Financial Operations Overview
Financial Results Financial Statements
Financial Statements Exhibits First-in-class Adult Stem Cell Products
Flexible Treatment Paradigm Foreign Current Exchange Rate Risk
Foreign Regulation Form 10-k
Form 10-q Former Name Address Changed Since Last Report
Forward Looking Statements Forward-looking Information
Forward-looking Statements Friedli Corporate Finance
Full 2007 Financial Highlights Full 2008 Financial Highlights
Full Current Highlights Full Highlights
Future Contractual Obligations Future Maturities Capital Lease Obligations
Future Maturities Notes Payable Capital Lease Obligations General
General Administrative Expenses General Compensation Policy
General Release Claims Genzyme
Genzyme Corporation-collaboration Agreement Genzyme Partnership United States Department Defense Contract
Governing Law Governing Law Consent Jurisdiction Agreement Shall Governed Laws
Government Terminate Federal Contracts Time Graft Versus Host Disease
Grants Plan-based Awards Gregory Barnhill
Gvhd Harry Carmitchel
Hart-scott-rodino Notification Highlights
Highlights Date Highlights Include
Highlights Recent Developments History Operating Losses Not Achieve Sustain Profitability
Holder Human Cellular Tissue-based Product
Human Mesenchymal Stem Cell Manufacturing Process Description Human Subjects Stem Cell Therapies Products Produced Expose
Important Findings Imposition Lien Other Permitted Liens Transferred Assets
Income Loss Per Common Share Income Tax Benefit Expense
Income Taxes Incorporation Recitals Set Forth Above Incorporated Reference Part
Indemnification Insurance Indemnified Party They Reasonably Require Purposes Determining Whether
Indemnity Insurance Index
Information Presented Current Report Form 8-k Contain Forward-looking Infringe Alleged Intellectual Property Rights Parties Adversely Affect
Initial Public Offering Initial Public Offering Non-cash Charges Reverse Stock Split
Initial Public Offering Proceeds Sales Registered Securities Initial Public Offering Reverse Stock Split
Intellectual Property Intellectual Property Confidentiality
Interest Expense Net Interest Expensenet
Interest Income Expense Net Interest Other Income Expense Net
Interest Rate Risk Interim Financial Statements
Internally Develop Commercialize Future Biologic Drug Candidates Introduction Overview
Inventions Shall Meaning Such Term Defined Agreement Inventory
Investments Available Sale Investments Available Sale Other Comprehensive Income
Investments Available Sale Other Comprehensive Income Loss Issuer Purchase Equity Securities Proceeds
Jay Moyes Jcr Pharmaceuticals Agreement
Jcr Pharmaceuticals Ltd-license Agreement Jdrf
Juvenile Diabetes Research Foundation Agreement Juvenile Diabetes Research Foundation-collaborative Agreement
Key Points Trial Large Scale Manufacturing
League Island Blvd Philadelphia 19112 Legal Proceedings
Level Leverage Osteocels Orthopedic Sales Infrastructure Biologic Drug Candidate
License Sublicense Rights Seller Respect Transferred Technology License Transferred Technology Except Licenses Standard Customer Agreement
Liquidity Lockup Agreement
Lode Debrabandere Long Term Business Prospects Depend Primarily Success Biologic
Long-term Incentive Compensation Loss Per Common Share
Managements Role Determining Executive Compensation Manufacturing
Manufacturing Agreement Manufacturing Assets Contemplated Hereunder Rescinded Following Consummation
Market Information Market Registrants Common Equity Related Stockholder Matters Issurer
Marketed Product Material Change Pricing Charged Seller Products
Material Impairments Maturity
Meeting Attendance Milestone Payments
Miscellaneous Most Significant Collaborative Arrangements Genzyme Corporation Ultimate Success
Multiple Applications Mutual Written Consent Purchaser Seller
New Venturetec Pine Loans Not Able Conduct Clinical Trials Properly Schedule Marketing
Not Able Manufacture Biologic Drug Candidates Quantities Sufficient Not Able Manufacture Osteocel Quantities Sufficient Expand Market
Not Able Obtain Maintain Orphan Drug Designation Biologic Not Able Raise Additional Capital Necessary Fund Operations
Not Able Recruit Retain Qualified Management Scientific Personnel Not Able Secure Maintain Research Institutions Conduct Clinical
Not Able Successfully Develop Commercialize Biologic Drug Candidates Not Applicable
Not Eligible Severance Benefits Not Receive Payments Available Terms Asset Purchase Agreement
Notes Condensed Financial Statements Notes Payable
Notes Payable Capital Lease Obligations Notes Payable Related Party Transactions
Notice 2007 Annual Meeting Stockholders Notice 2009 Annual Meeting Stockholders
Notice Notices Contemplated Agreement Shall Sent Each Parties Now Therefore
Number 001-32966 Number-
Number- 001-32966 Nuvasive Inc
Obligations Unsecured Off-balance Sheet Arrangements
Option Exercises Stock Vested Organizational Governing Documents Approval
Osiris Completed Development Product Formulation Suitable Administration Humans Osiris Completed Fda Approved Comparability Study Consistency Lots
Osiris Completed Several Inds Demonstrating Strong Safety Profile Osiris Completed Small-scale Process Development Qualification Prochymal Currently
Osiris Currently Submits Documents Fda Electronically Through Secure Osiris Materials Specifications Numbers 90055 90067 90080 90081
Osiris Representations Covenants Agreements Osiris Shall Perform Satisfy Comply Material Aspects Covenants
Osiris Shall Store Phase Product Cgmp-controlled Conditions Following Osiris Therapeutics
Osiris Therapeutics Announces Private Placement Osiris Therapeutics Inc
Osiris Therapeutics Reports 2007 Financial Results Osiris Therapeutics Secures Financing Commitment Chairman Largest Shareholder
Osirisschwartz-prcom Osteocel
Osteocel Biologic Drug Candidates Derived Human Bone Marrow Osteocel Biologic Drug Candidates Derived Human Tissue Bone
Other Other Bids
Other Corporate Developments Other Covenants
Other Events Other Fees
Other Financings Other Information
Other Matters Other Regulations
Overview Page
Part Other Information Parties Shall Mean Osiris Nuvasive Party
Patent Position Not Adequately Protect Osteocel Biologic Drug Patent Position Not Adequately Protect Products Others Compete
Payment Connection Subscription Agreement Subject Acceptance Subscriber Hereby Performance Data
Performance Shares Performance Units
Peter Friedli Phase Acute Gvhd Trial
Phase Chondrogen Trial Phase Chronic Obstructive Pulmonary Disease Trial
Phase Clinical Trial-acute Myocardial Infarction Phase Clinical Trial-animal Rule-acute Radiation Syndrome
Phase Clinical Trial-biologics Refractory Crohns Disease Phase Clinical Trial-chronic Obstructive Pulmonary Disease
Phase Clinical Trial-early Onset Type Diabetes Phase Clinical Trial-first Line Treatment Acute Gvhd
Phase Clinical Trial-steroid Refractory Acute Gvhd Phase Clinical Trial-type Early Onset Diabetes
Phase Type Diabetes Trial Plan Description
Please Detach Mail Envelope Provided Postage Prepaid Registered Certified Each Case Appropriate Addresses
Potential Stem Cell Therapies Treat Diseases Not Realized Pre-approval Policy
Preclinical Study-acute Radiation Syndrome Preferred Stock Conversion
Preferred Stock Rights Preferences Preparation Proxy Statement Stockholder Meeting
Principal Accounting Fees Services Privacy Law
Private Placement Pro Forma Financial Information
Pro Forma Information Sfas 123 Periods Prior 2006 Processing Storage Facility Clinical Manufacturing Facilities Damaged Destroyed
Prochymal Prochymal Chondrogen Development Commercialization
Prochymal Development Treat Acute Radiation Syndrome Prochymal Graft Host Disease Gvhd
Prochymal Heart Attack Patients Interim Analysis Procurement Supply Donors
Producing Marketing Approved Drug Other Medical Product Subject Product Development Programs Based Novel Technologies Inherently Risky
Product Dose Product Royalties
Production Biologic Drug Candidates Production Osteocel
Products Product Liability Promissory
Properties Property Equipment
Proposal Proposal 1-election Director Nominees
Proposal 3-independent Registered Public Accounting Firm Proposal Approval Amended Restated 2006 Omnibus Plan
Proposed Sale Not Completed Conditions Closing Satisfied Waived Provacel
Proxy Being Solicited Board Directors Osiris Therapeutics Inc Public Announcement
Public Disclosure Pulmonary Data
Purchaser Purchaser Reasonably Request Order Comply Requirements Financial Statements
Purpose Effective Date Definitions Pursuant 302 Sarbanes-oxley Act 2002
Pursuant 906 Sarbanes-oxley Act 2002 Subsections 1350 Chapter Pursuant Securities Exchange Act 1934
Quantitative Qualitative Disclosures Market Risk Radio Television Advertisement Other Form General Advertising Solicitation
Randal Mills Ratify Independent Registered Public Accountants
Rats Small Animal Recent Accounting Pronouncements Did Not Material Impact Consolidated
Recent Accounting Pronouncements Material Impact Future Consolidated Financial Recent Full Highlights
Recent Sales Unregistered Securities Recitals
Reclassifications Referral Fees Costs
Registrants Telephone Number Including Area Code Securities Registered Registration Rights
Regulation Disclosure Related Party Expenses
Related Party Transactions Remainder Page Intentionally Blank
Remainder Page Left Intentionally Blank Remedies Survival
Report Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Representations Warranties Representations Warranties Covenants Agreements Set Forth Agreement Time
Representations Warranties Purchaser Representations Warranties Represents Warrants Holder Follows
Research Collaboration Agreements Deferred Revenue Research Collaboration Agreements Government Contract
Research Development Costs Research Development Expenses
Restricted Stock Restrictive Covenants
Results Operations Results Operations Financial Condition
Retained Liabilities Retirement Post-employment Benefits
Revenue Revenue Continuing Operations
Revenue Recognition Revenues Continuing Operations
Revoke Proxy Right Negotiation Purchase Option
Rights Risk Factors
Risks Risks Related Intellectual Property
Safety Data Sales Marketing Distribution
Schedule 14a Schedule 14a Rule 14a-101 Information Required Proxy Statement
Scientific Background Securities Authorized Issuance Equity Compensation Plans
Securities Registered Pursuant Act Security Ownership Certain Beneficial Owners Management Related Stockholder
Segment Reporting Seller
Seller Benefit Plan Maintained Outside Jurisdiction United States Seller Owns Valid Rights Transferred Technology
Seller Shall Make Employment Files Employees Available Inspection Seller Sole Exclusive Beneficial Record Owner Transferred Technology
Seq Severability
Share Based Payments Related Parties Share-based Compensation
Shares Present Order Hold Annual Meeting Shares Voted Not Return Proxy Card
Short-term Investments Signature
Signatures Significant New Accounting Pronouncement
Significant New Accounting Pronouncements Six-month Interim Data
Special Meeting Statement Operations Data
Stem Cell Source Stem Cell Therapies Human Subjects Expose Product Liability
Stock Appreciation Rights Stock Options
Stock Performance Graph Stock-based Compensation
Stockholder Communications Board Stockholder Proposals Nominations Director
Stockholders Strategy
Study Cell Delivery Technique Study Product Stability After Thaw
Study Shipping Stability Submission Matters Vote Securities Holders
Submission Matters Vote Security Holders Subscriber Information
Subscriber Understands Federal State Government Agency Passed Recommendation Subscription Agreement
Subscription Agreement Accepted Been Duly Authorized Executed Delivered Subscription Documents
Subscription Instructions Subsections 1350 Chapter Title United States Code
Subsequent Event Collaboration Agreement Genzyme Corp Subsequent Events
Successful Commercialization Biologic Drug Candidates Other Potential Stem Successfully Commercialize Lead Stem Cell Therapy Prochymal
Such Person Entity Prohibited Investing Ofac Administered Sanctions Summary Compensation Table
Summary Osiris Progress Completing Sections C31 Clin 0001aa Supplemental Cash Flow Information
Supply Agreement Table Contents
Taxes Term
Term Termination Termination
Termination Certain Contracts Termination Date
Therapeutics Inc Third-party Collaborators Help Develop Commercialize Products Ability Such
Third-party Manufacturers Increase Risk Not Adequate Quantities Biologic Time Determination Dispute Mechanism
Trading Price Shares Common Stock Highly Volatile Purchasers Transferred Assets Excluded Time Transfer
Trial Trial Highlights
Type Diabetes Unable Protect Confidentiality Proprietary Information Know-how Competitive Position
Unable Protect Confidentiality Proprietary Information Trade Secrets Know-how Unfavorable Federal Government Audit Results Subject Penalties Sanctions
Unit Group Covered Vice Presidents Executive Officers Eligible Universal Compatibility
Unregistered Sales Equity Securities Unregistered Sales Securities
Valuation Long-lived Assets Voluntary Execution Executive
Vote Voting
Warrants Washington 20549
Web Cast Conference Call Webcast Conference Call
What Receive Proxy Card What Vote Required Approve Each Proposal Votes Counted
Whereas Whether Not Intend Present Meeting Urged Fill Out
Witness Whereof 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki